Lecanemab for Alzheimer's disease: Discussing risks and benefits is key

Canada precocious approved lecanemab to dainty aboriginal Alzheimer's disease, but the objective benefits are modest, it carries a hazard of superior adverse effects, and attraction is complex. An nonfiction successful the Canadian Medical Association Journal provides an overview of the medicine and advises wellness attraction professionals to prosecute successful shared decision-making with patients and caregivers to assistance them recognize the imaginable risks and benefits.